MX2024004366A - Composiciones y métodos para tratar la deficiencia de alfa-1 antitripsina. - Google Patents

Composiciones y métodos para tratar la deficiencia de alfa-1 antitripsina.

Info

Publication number
MX2024004366A
MX2024004366A MX2024004366A MX2024004366A MX2024004366A MX 2024004366 A MX2024004366 A MX 2024004366A MX 2024004366 A MX2024004366 A MX 2024004366A MX 2024004366 A MX2024004366 A MX 2024004366A MX 2024004366 A MX2024004366 A MX 2024004366A
Authority
MX
Mexico
Prior art keywords
compositions
methods
antitrypsin deficiency
treating alpha
alpha
Prior art date
Application number
MX2024004366A
Other languages
English (en)
Inventor
Laura Sepp-Lorenzino
Zachary W Dymek
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of MX2024004366A publication Critical patent/MX2024004366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan composiciones y métodos para expresar alfa 1 antitripsina (AAT) en una célula hospedadora. También se proporcionan composiciones y métodos para tratar sujetos que tienen deficiencia de alfa 1 antitripsina (AATD).
MX2024004366A 2021-10-15 2022-10-14 Composiciones y métodos para tratar la deficiencia de alfa-1 antitripsina. MX2024004366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256365P 2021-10-15 2021-10-15
PCT/US2022/078140 WO2023064918A1 (en) 2021-10-15 2022-10-14 Compositions and methods for treating alpha-1 antitrypsin deficiency

Publications (1)

Publication Number Publication Date
MX2024004366A true MX2024004366A (es) 2024-06-21

Family

ID=84389257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004366A MX2024004366A (es) 2021-10-15 2022-10-14 Composiciones y métodos para tratar la deficiencia de alfa-1 antitripsina.

Country Status (9)

Country Link
EP (1) EP4416289A1 (es)
KR (1) KR20240100492A (es)
CN (1) CN118355118A (es)
AU (1) AU2022366984A1 (es)
CA (1) CA3235312A1 (es)
IL (1) IL312033A (es)
MX (1) MX2024004366A (es)
TW (1) TW202330919A (es)
WO (1) WO2023064918A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113195721A (zh) * 2018-10-18 2021-07-30 英特利亚治疗股份有限公司 治疗α-1抗胰蛋白酶缺乏症的组合物和方法

Also Published As

Publication number Publication date
EP4416289A1 (en) 2024-08-21
AU2022366984A1 (en) 2024-04-18
IL312033A (en) 2024-06-01
WO2023064918A1 (en) 2023-04-20
CA3235312A1 (en) 2023-04-20
TW202330919A (zh) 2023-08-01
KR20240100492A (ko) 2024-07-01
CN118355118A (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
PH12021550842A1 (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
AU2018372763A1 (en) Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
NO20070561L (no) Sammensetninger og fremgangsmater for a behandle oyesykdommer og tilstander.
HK1074592A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE69529912D1 (de) Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor
PL1789419T3 (pl) Inhibitory gyrazy i ich zastosowanie
MX2022009658A (es) Composiciones y metodos para la edicion de genes de calicreina (klkb1).
EP4011376A3 (en) Combination of an alk inhibitor and an egfr inhibitor for treating cancer
ZA202209970B (en) Neurotoxin compositions for use in treating cardiovascular disorders
MX2024004366A (es) Composiciones y métodos para tratar la deficiencia de alfa-1 antitripsina.
WO2000071153A3 (de) Arzneimittel zur lokalen anwendung, das fibrinogen, thrombin, transglutaminasen und proteinaseinhibitoren enthält
UY27971A1 (es) Derivados de piperidina
MX2024002988A (es) Composiciones y metodos moduladores de la serpina.
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
EP4157290A4 (en) COMPOSITIONS, THEIR USES IN THERAPY AND METHODS THEREFOR
FR2872431B1 (fr) Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire
WO2020232063A8 (en) Synergistic combinations of arginine-producing bacteria and/or ammonia-consuming bacteria and checkpoint inhibitors and methods of use thereof
DK1594456T3 (da) Anvendelse af en sammensætning indeholdende vitamin K1-oxid eller et derivat deraf til behandling og/eller forebyggelse af dermatologiske læsioner hos pattedyr
WO2004016739A3 (en) Cell modulation using a cytoskeletal protein
WO2002024179A3 (en) Method for reducing toxicity of combined chemotherapies
WO2023240193A3 (en) Fitusiran for the treatment of hemophilia a and b in pediatric patients
AU2021324891A8 (en) Compositions and methods for treating or preventing hereditary angioedema
WO2003061574A3 (en) Prevention of cisplatin induced deafness
UA90162C2 (ru) Фармацевтическая композиция на основе ингибитора обратной транскриптазы и мелдония
WO2024073432A3 (en) Compositions and methods for treating inflammatory disease